Rosuvastatin is a synthetic statin that represents an advance in the pharmacologic and
clinical properties of statins. Relative to other statins, rosuvastatin possesses a greater …

Introduction: Statins are powerful lipid-lowering agents which reduce cardiovascular (CV)–
related morbidity and mortality. However, a large proportion of patients cannot attain the …

Background: There is an increasing body of evidence to support the benefits of reducing low-
density lipoprotein cholesterol (LDL-C) levels and this has been reflected in a lowering of …

Patients at risk of coronary heart disease may not achieve recommended low-density
lipoprotein (LDL) cholesterol goals on statin monotherapy. This study was designed to …

Cardiovascular disease is the leading cause of death in the US and other industrialised
societies. Rosuvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, is the …

Statins are the lipid-lowering drug family of first choice in situations of hypercholesterolemia
or mixed dyslipidemia with predominant increase in cholesterol. The evidence shows …

Many hypercholesterolaemic patients fail to achieve target low-density lipoprotein
cholesterol (LDL-C) levels in clinical practice. In part, this failure is related to inadequate …

Methods—Discovery Belux is an open-label, multicentre, randomised, phase IIIb, parallel
group study comparing the efficacy of rosuvastatin (RSV) and atorvastatin (ATV) on changes …

On the basis of large randomized clinical trials, pharmacological antagonists of HMG-CoA
reductase (statins) have become increasingly used in clinical practice for the prevention of …